NO2686520T3 - - Google Patents
Info
- Publication number
- NO2686520T3 NO2686520T3 NO12759983A NO12759983A NO2686520T3 NO 2686520 T3 NO2686520 T3 NO 2686520T3 NO 12759983 A NO12759983 A NO 12759983A NO 12759983 A NO12759983 A NO 12759983A NO 2686520 T3 NO2686520 T3 NO 2686520T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493536P | 2011-06-06 | 2011-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2686520T3 true NO2686520T3 (ko) | 2018-03-17 |
Family
ID=47262177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO12759983A NO2686520T3 (ko) | 2011-06-06 | 2012-03-05 |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US9145366B2 (ko) |
| EP (5) | EP2718265B1 (ko) |
| JP (6) | JP6290781B2 (ko) |
| KR (5) | KR102059366B1 (ko) |
| CN (1) | CN106518759B (ko) |
| AU (4) | AU2012268426B2 (ko) |
| CA (2) | CA3135440A1 (ko) |
| CY (4) | CY1117177T1 (ko) |
| DK (4) | DK3000808T3 (ko) |
| ES (4) | ES2771232T3 (ko) |
| HK (3) | HK1196616A1 (ko) |
| HR (4) | HRP20211916T1 (ko) |
| HU (4) | HUE026096T2 (ko) |
| IL (1) | IL229775A (ko) |
| LT (3) | LT3000808T (ko) |
| MX (2) | MX337216B (ko) |
| NO (1) | NO2686520T3 (ko) |
| PL (4) | PL2718265T3 (ko) |
| PT (4) | PT3290404T (ko) |
| RS (3) | RS59902B1 (ko) |
| RU (2) | RU2602083C2 (ko) |
| SI (4) | SI3683209T1 (ko) |
| SM (1) | SMT201600013B (ko) |
| WO (1) | WO2012170377A1 (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4095127A1 (en) | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| NO2686520T3 (ko) | 2011-06-06 | 2018-03-17 | ||
| LT3007695T (lt) * | 2013-06-13 | 2024-03-25 | Akebia Therapeutics, Inc. | Kompozicijos ir būdai, skirti anemijos gydymui |
| US9701636B2 (en) * | 2013-11-15 | 2017-07-11 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| WO2016034108A1 (zh) | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| EP3247355A4 (en) | 2015-01-23 | 2018-06-13 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| WO2016153996A1 (en) * | 2015-03-20 | 2016-09-29 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| PE20180189A1 (es) | 2015-04-01 | 2018-01-23 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia |
| CA3046377C (en) * | 2016-12-13 | 2021-03-30 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and processes for preparation thereof |
| US10919843B2 (en) * | 2017-03-29 | 2021-02-16 | Emerald Health Pharmaceuticals Inc. | Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| TW202406895A (zh) | 2018-05-09 | 2024-02-16 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
| WO2020075199A1 (en) | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
| US11970450B2 (en) | 2018-11-28 | 2024-04-30 | Sandoz Ag | Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor |
| CN113767089A (zh) | 2019-04-26 | 2021-12-07 | 株式会社钟化 | 伐度司他中间体的制造方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN111087343B (zh) * | 2019-11-29 | 2022-02-18 | 万华化学集团股份有限公司 | 一种羟基吡啶配体及其制备方法和催化应用 |
| US20230159462A1 (en) * | 2019-12-10 | 2023-05-25 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| EP4094832A4 (en) | 2020-01-24 | 2024-04-17 | Aps Japan Co Ltd | PHOTOCATALYST UNIT AND MASK PROVIDED WITH A PHOTOCATALYST UNIT |
| WO2022006427A1 (en) | 2020-07-02 | 2022-01-06 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
| GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
| WO2023111990A1 (en) | 2021-12-17 | 2023-06-22 | Akebia Therapeutics, Inc. | Selective phd1 inhibitor compounds, compositions, and methods of use |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) * | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) * | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| TW219933B (ko) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ES2101420T3 (es) * | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| DK0650961T3 (da) | 1993-11-02 | 1997-09-15 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler. |
| TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| WO1997041103A1 (de) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1024134A4 (en) | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE69919349T2 (de) | 1998-03-23 | 2005-01-13 | Aventis Pharmaceuticals Inc. | Piperidinyl- und n-amidinopiperidinyl-derivate |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| AU2002241154A1 (en) | 2001-03-21 | 2002-10-03 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| US20030153503A1 (en) | 2001-12-06 | 2003-08-14 | Klaus Stephen J. | Methods of increasing endogenous erythropoietin (EPO) |
| MXPA04011310A (es) | 2002-05-17 | 2005-02-14 | Celgene Corp | Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades. |
| US7163951B2 (en) | 2002-08-29 | 2007-01-16 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| ATE452204T1 (de) | 2002-10-16 | 2010-01-15 | Isis Innovation | Screening-methoden unter verwendung eines strukturmodells von fih |
| JP2006522735A (ja) | 2002-11-21 | 2006-10-05 | イーライ リリー アンド カンパニー | ミックス系統キナーゼモジュレータ |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
| PT1644336E (pt) | 2003-06-06 | 2011-04-21 | Fibrogen Inc | Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| NZ551632A (en) | 2004-05-28 | 2009-09-25 | Fibrogen Inc | HIF prolyl hydroxylase activity assay |
| WO2005115984A2 (en) | 2004-05-31 | 2005-12-08 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activitated k channel opener |
| KR20070083484A (ko) | 2004-07-14 | 2007-08-24 | 피티씨 테라퓨틱스, 인크. | Ｃ형 간염 치료 방법 |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| WO2006084210A2 (en) | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| AU2006254897A1 (en) | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a HIF-alpha stabilising agent |
| MX2007016160A (es) | 2005-06-15 | 2008-03-07 | Fibrogen Inc | Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer. |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| WO2007047194A2 (en) | 2005-10-11 | 2007-04-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating mitf-related disorders |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| BRPI0706377A2 (pt) | 2006-01-09 | 2011-03-22 | Btg Int Ltd | moduladores de fator -1 induzìvel por hipoxia e usos relacionados |
| EP1983823A1 (en) | 2006-01-17 | 2008-10-29 | VIB vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| EP4095127A1 (en) * | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| AU2008241577B2 (en) | 2007-04-18 | 2011-04-07 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| AU2008241503A1 (en) | 2007-04-18 | 2008-10-30 | Merck Sharp & Dohme Corp. | Novel 1,8-naphthyridine compounds |
| WO2008137060A1 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| JP5349462B2 (ja) | 2007-05-16 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | スピロインダロン |
| US8796253B2 (en) | 2007-05-18 | 2014-08-05 | Bayer Intellectual Property Gmbh | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| CN101868251B (zh) | 2007-08-06 | 2012-10-10 | 千寿制药株式会社 | 含有HIF-1α和HIF-2α表达抑制物质的药物 |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| EP2188295A4 (en) | 2007-08-10 | 2011-11-16 | Crystalgenomics Inc | PYRIDINE DERIVATIVES AND METHODS OF USE |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| US20100305133A1 (en) | 2007-11-30 | 2010-12-02 | Smithkline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| WO2009089547A1 (en) | 2008-01-11 | 2009-07-16 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| PT2268618E (pt) * | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| US20090228298A1 (en) * | 2008-03-04 | 2009-09-10 | The General Electric Company | System and method of morphology feature analysis of physiological data |
| EP2268143A4 (en) * | 2008-03-20 | 2012-06-27 | Forest Lab Holdings Ltd | NEW PIPERIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COA DESATURASE |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| KR20110033291A (ko) | 2008-07-23 | 2011-03-30 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| KR20110063537A (ko) | 2008-09-15 | 2011-06-10 | 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 | 전이성 악성 흑색종 및 기타 암에 대한 항암 약물 및 이와 관련한 용도 |
| CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| PT2415771E (pt) * | 2009-03-31 | 2013-10-03 | Kissei Pharmaceutical | Derivado de indolizina e sua utilização para fins médicos |
| MX2012005275A (es) | 2009-11-06 | 2012-06-19 | Aerpio Therapeutics Inc | Composiciones y metodos para tratar colitis. |
| MX2013014310A (es) | 2011-06-06 | 2014-01-23 | Akebia Therapeutics Inc | Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer. |
| NO2686520T3 (ko) | 2011-06-06 | 2018-03-17 | ||
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| US9206134B2 (en) | 2011-07-22 | 2015-12-08 | Beijing Betta Pharmaceuticals Co. Ltd. | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| LT3007695T (lt) | 2013-06-13 | 2024-03-25 | Akebia Therapeutics, Inc. | Kompozicijos ir būdai, skirti anemijos gydymui |
| CN105979779A (zh) | 2013-08-16 | 2016-09-28 | 俄亥俄州国家创新基金会 | 调整dna甲基化的组合物和方法 |
| US9701636B2 (en) | 2013-11-15 | 2017-07-11 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| MX2016009331A (es) | 2014-01-23 | 2016-10-26 | Akebia Therapeutics Inc | Composiciones y metodos para tratar enfermedades oculares. |
| EP3247355A4 (en) | 2015-01-23 | 2018-06-13 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| WO2016153996A1 (en) | 2015-03-20 | 2016-09-29 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| PE20180189A1 (es) | 2015-04-01 | 2018-01-23 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia |
| TW202406895A (zh) | 2018-05-09 | 2024-02-16 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
-
2012
- 2012-03-05 NO NO12759983A patent/NO2686520T3/no unknown
- 2012-06-05 LT LTEP15189822.8T patent/LT3000808T/lt unknown
- 2012-06-05 SI SI201231969T patent/SI3683209T1/sl unknown
- 2012-06-05 DK DK15189822.8T patent/DK3000808T3/da active
- 2012-06-05 PT PT171913627T patent/PT3290404T/pt unknown
- 2012-06-05 RU RU2013158640/04A patent/RU2602083C2/ru active
- 2012-06-05 HU HUE12796374A patent/HUE026096T2/en unknown
- 2012-06-05 HU HUE15189822A patent/HUE034975T2/en unknown
- 2012-06-05 DK DK19214405.3T patent/DK3683209T3/da active
- 2012-06-05 DK DK17191362.7T patent/DK3290404T3/da active
- 2012-06-05 CN CN201610967348.7A patent/CN106518759B/zh active Active
- 2012-06-05 JP JP2014514536A patent/JP6290781B2/ja active Active
- 2012-06-05 KR KR1020197007630A patent/KR102059366B1/ko active IP Right Grant
- 2012-06-05 LT LTEP19214405.3T patent/LT3683209T/lt unknown
- 2012-06-05 RS RS20200130A patent/RS59902B1/sr unknown
- 2012-06-05 AU AU2012268426A patent/AU2012268426B2/en active Active
- 2012-06-05 SI SI201231114T patent/SI3000808T1/en unknown
- 2012-06-05 HU HUE17191362A patent/HUE048044T2/hu unknown
- 2012-06-05 KR KR1020207029586A patent/KR102293016B1/ko active IP Right Grant
- 2012-06-05 ES ES17191362T patent/ES2771232T3/es active Active
- 2012-06-05 DK DK12796374.2T patent/DK2718265T3/en active
- 2012-06-05 EP EP12796374.2A patent/EP2718265B1/en active Active
- 2012-06-05 MX MX2013014228A patent/MX337216B/es active IP Right Grant
- 2012-06-05 LT LTEP17191362.7T patent/LT3290404T/lt unknown
- 2012-06-05 EP EP21206374.7A patent/EP4026829A1/en active Pending
- 2012-06-05 EP EP15189822.8A patent/EP3000808B1/en active Active
- 2012-06-05 ES ES15189822.8T patent/ES2647602T3/es active Active
- 2012-06-05 PL PL12796374T patent/PL2718265T3/pl unknown
- 2012-06-05 PT PT192144053T patent/PT3683209T/pt unknown
- 2012-06-05 EP EP19214405.3A patent/EP3683209B1/en active Active
- 2012-06-05 PT PT127963742T patent/PT2718265E/pt unknown
- 2012-06-05 HR HRP20211916TT patent/HRP20211916T1/hr unknown
- 2012-06-05 KR KR1020197007633A patent/KR102032864B1/ko active IP Right Grant
- 2012-06-05 PT PT151898228T patent/PT3000808T/pt unknown
- 2012-06-05 KR KR1020197037296A patent/KR102171315B1/ko active IP Right Grant
- 2012-06-05 KR KR1020147000297A patent/KR102000485B1/ko active IP Right Grant
- 2012-06-05 CA CA3135440A patent/CA3135440A1/en active Pending
- 2012-06-05 ES ES12796374.2T patent/ES2559850T3/es active Active
- 2012-06-05 CA CA2838194A patent/CA2838194C/en active Active
- 2012-06-05 MX MX2015016579A patent/MX347709B/es unknown
- 2012-06-05 US US13/488,554 patent/US9145366B2/en active Active
- 2012-06-05 RS RS20171181A patent/RS56580B1/sr unknown
- 2012-06-05 WO PCT/US2012/040833 patent/WO2012170377A1/en active Application Filing
- 2012-06-05 RU RU2016139352A patent/RU2764667C2/ru active
- 2012-06-05 PL PL15189822T patent/PL3000808T3/pl unknown
- 2012-06-05 PL PL19214405T patent/PL3683209T3/pl unknown
- 2012-06-05 SI SI201231729T patent/SI3290404T1/sl unknown
- 2012-06-05 PL PL17191362T patent/PL3290404T3/pl unknown
- 2012-06-05 RS RS20160013A patent/RS54517B1/en unknown
- 2012-06-05 HU HUE19214405A patent/HUE057571T2/hu unknown
- 2012-06-05 EP EP17191362.7A patent/EP3290404B1/en active Active
- 2012-06-05 SI SI201230432T patent/SI2718265T1/sl unknown
- 2012-06-05 ES ES19214405T patent/ES2900572T3/es active Active
-
2013
- 2013-12-03 IL IL229775A patent/IL229775A/en active IP Right Grant
-
2014
- 2014-10-10 HK HK14110125.1A patent/HK1196616A1/zh unknown
-
2015
- 2015-08-24 US US14/833,222 patent/US9776969B2/en active Active
- 2015-12-23 HR HRP20151416T patent/HRP20151416T1/hr unknown
-
2016
- 2016-01-14 CY CY20161100037T patent/CY1117177T1/el unknown
- 2016-01-15 SM SM201600013T patent/SMT201600013B/it unknown
- 2016-04-07 HK HK16104004.8A patent/HK1216173A1/zh unknown
-
2017
- 2017-04-12 AU AU2017202414A patent/AU2017202414B2/en active Active
- 2017-08-31 US US15/692,255 patent/US10246416B2/en active Active
- 2017-11-13 HR HRP20171740TT patent/HRP20171740T1/hr unknown
- 2017-11-15 CY CY20171101202T patent/CY1119605T1/el unknown
-
2018
- 2018-02-08 JP JP2018020595A patent/JP6510094B2/ja active Active
- 2018-09-05 HK HK18111429.8A patent/HK1252109A1/zh unknown
- 2018-10-15 AU AU2018250355A patent/AU2018250355B2/en active Active
-
2019
- 2019-03-13 US US16/352,705 patent/US10738010B2/en active Active
- 2019-04-03 JP JP2019070979A patent/JP6816195B2/ja active Active
-
2020
- 2020-02-03 CY CY20201100087T patent/CY1122639T1/el unknown
- 2020-02-06 HR HRP20200197TT patent/HRP20200197T1/hr unknown
- 2020-07-06 US US16/921,273 patent/US11267785B2/en active Active
- 2020-07-07 AU AU2020204528A patent/AU2020204528B2/en active Active
- 2020-12-23 JP JP2020213442A patent/JP7039682B2/ja active Active
-
2021
- 2021-12-08 CY CY20211101079T patent/CY1124874T1/el unknown
-
2022
- 2022-01-31 US US17/589,118 patent/US20230002323A1/en active Pending
- 2022-03-09 JP JP2022035813A patent/JP7284309B2/ja active Active
-
2023
- 2023-05-18 JP JP2023081959A patent/JP2023103414A/ja active Pending